![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
Pharma, Biotech and Generics Industry News | The Pharmaletter
Jan 2, 2025 · Shares of US drugmaker Vertex Pharmaceuticals jumped 8.4% to $475.00 in after-hours trading yesterday after it announced that the US Food and Drug Administration (FDA) has approved Journavx (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain.
BioAge Lab | The Pharmaletter
Jan 30, 2025 · A clinical-stage biopharma company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. The company has nominated a member of this class, the orally available, small-molecule brain-penetrant NLRP3 inhibitor BGE-102, as a ...
January 2025 EMA-CHMP recommendations | The Pharmaletter
Jan 31, 2025 · The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines for approval at its January 2025 meeting, as well as some biosimilars. The CHMP recommended granting a marketing authorization for US pharma giant Merck & Co’s (NYSE: MRK) Capvaxive ...
Active deal-making day for Boehringer, with two ADC collabs
Jan 9, 2025 · German family-owned pharma major Boehringer Ingelheim has licensed antibody-drug conjugates ADC technology from Netherlands-based Synaffix, a Lonza (SWX: LONN) company. This new partnership significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the ...
Trump vs Harris—who's on Big Pharma's side? | Pharmaceutical
Sep 22, 2024 · In the 2024 US presidential election, health policy will remain a key issue for pharma. Both Donald Trump and Kamala Harris have criticized high drug prices, raising uncertainty for the industry. While Trump targeted generics, biosimilars, and international price comparisons during his term, Harris has been associated with pricing transparency and the Inflation Reduction Act (IRA), which ...
FDA panel flags risks as AstraZeneca seeks full Andexxa approval
Nov 22, 2024 · AstraZeneca faces challenges in securing full FDA approval for Andexxa, its anticoagulant reversal therapy, due to safety concerns raised during an advisory committee meeting. Despite positive data on brain bleeds, higher clotting events in patients treated with Andexxa have cast doubt on its benefits.
Concerns about tablet-splitting of muscle relaxant
May 23, 2004 · Back and neck pain sufferers who divide the most frequently-prescribed muscle relaxant may be getting anywhere from half to one-and-a-half times the amount of medicine they believe they are taking, suggests a new study examining the practice of tablet-splitting.
Ascentage Pharma sets terms for $149 million US IPO
Jan 22, 2025 · Suzhou, China-based Ascentage Pharma revealed that it plans to raise $149 million by offering 7.3 million American Depositary Shares (ADSs) at $20.34, the as-converted January 17 close of its shares on the Hong Kong Stock Exchange.
Pharma USA 2025 - The Pharmaletter
Jan 30, 2025 · The two day event offers a variety of means for networking and collaboration: Hackathons offering a hyper-interactive session where attendees work as a team to hack strategic issues.
Glaxo Wellcome & SmithKline Beecham merger - updated story
Jan 19, 2000 · Glaxo Wellcome and SmithKline Beecham have agreed to merge, in a dealwhich will create the largest pharmaceutical company in the world with a market capitalization of some L114 billion ($186.65 billion), annual sales of around L15 billion and a global market share estimated at 7.3%.